Acquired resistance to the Hedgehog pathway inhibitor vismodegib due to smoothened mutations in treatment of locally advanced basal cell carcinoma - 16/10/14

Tjinta Brinkhuizen, MD ^{a, f, ⁎} , Marie G. Reinders, MD ^{a, f}, Michel van Geel, MD, PhD ^{a, b, f}, Annelot J.L. Hendriksen, MD ^a, Aimée D.C. Paulussen, MD, PhD ^b, Véronique J. Winnepenninckx, MD, PhD ^{c, f}, Kristien B. Keymeulen, MD, PhD ^{d, f}, Patricia M.M.B. Soetekouw, MD, PhD ^{e, f}, Maurice A.M. van Steensel, MD, PhD ^{a, b, f, g}, Klara Mosterd, MD, PhD ^{a, f}

^a Department of Dermatology, Maastricht University Medical Center, Maastricht, The Netherlands 

^b Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, The Netherlands 

^c Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands 

^d Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands 

^e Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands 

^f GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands 

^g Immunos, Institute of Medical Biology, Singapore 

^∗Correspondence to: Tjinta Brinkhuizen, MD, Maastricht University Medical Center, Department of Dermatology, P Debyelaan 25, PO Box 5800, 6202 AZ Maastricht, The Netherlands.